<DOC>
	<DOCNO>NCT00002763</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . It know whether give high-dose low-dose interferon alfa effective therapy treat patient stage III melanoma . PURPOSE : Randomized phase III trial compare effectiveness high- low-dose interferon alfa therapy follow surgery treat patient stage III melanoma .</brief_summary>
	<brief_title>High-Dose Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery Treating Patients With Stage III Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate time distant metastasis , death due melanoma , overall survival patient high-risk stage III melanoma treat 10 MU interferon alfa ( IFN-A ) 4 week follow 1 year IFN-A 10 MU three time per week vs. 2 year IFN-A 5 MU three time per week vs. observation alone . II . Assess toxicity associate IFN-A . III . Compare quality life , cost , compliance associate treatment regimen . OUTLINE : Randomized study . Following definitive surgical resection , patient randomly assign 2:2:1 ratio Arms A , B , C , respectively . Arm A : Biological Response Modifier Therapy . Interferon alfa-2b ( Schering ) , IFN-A , NSC-377523 . Higher dose . Arm B : Biological Response Modifier Therapy . IFN-A . Lower dose . Arm C : Control . Observation . PROJECTED ACCRUAL : A total 1,000 patient enter approximately 4 year multicenter study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cutaneous melanoma one follow category : T4 , N0 , M0 Deep primary tumor Breslow depth great 4.0 cm Tx , N1 , M0 Primary tumor regional lymph node metastases find lymphadenectomy clinically undetectable Tx , N2 , M0 Clinically apparent regional lymph node metastasis ( synchronous metachronous ) confirm lymphadenectomy Definitive surgical resection lymphadenectomy pathologically confirm adequate surgical margin require Minimum 2 cm margin primary lesion Breslow depth great 2 mm Distal interphalangeal amputation require subungual melanoma No primary melanoma originate apart skin No multiple transit metastasis extremity No lymph node involvement outside operative area resect radical neck , axillary lymph node , ilioinguinal dissection PATIENT CHARACTERISTICS : Age : 16 75 Performance status : ECOG 0 1 Hematopoietic : WBC least 4,000 Platelets least 125,000 Hemoglobin least 9.8 g/dL ( 6.1 mmol/L ) Hepatic : Bilirubin great 2 time normal AST great 2 time normal Renal : Creatinine great 1.6 mg/dL ( 140 micromoles/L ) Cardiovascular : No ventricular supraventricular arrhythmia require treatment No congestive heart failure ( NYHA class 3/4 status ) Other : No uncontrolled infection No requirement ongoing steroid , NSAIDs , immunomodulators No organic brain syndrome significant impairment basal cognitive function No psychiatric disorder would preclude study participation would exacerbate study therapy ( e.g. , depression ) No second malignancy except : In situ cervical cancer Nonmelanomatous skin cancer No pregnant nursing woman PRIOR CONCURRENT THERAPY : No prior treatment protocol patient recurrent melanoma regional lymph nod No preoperative infusion perfusion therapy Biologic therapy : No prior adjuvant immunotherapy Chemotherapy : No prior adjuvant systemic chemotherapy No prior anthracyclines Endocrine therapy : Not specify Radiotherapy : No prior adjuvant radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>